« Back to Record
Citation APA

De Witte, T., Baron, F., Suciu, S., Meert, L., Halkes, C. C., Selleslag, D., Bron, D., Amadori, S., Willemze, R., & Muus, P. (2015). Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Annals of hematology, 94(12), 1981-1989. doi:10.1007/s00277-015-2486-9


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/227064

De Witte, T., Baron, F., Suciu, S., Meert, L., Halkes, C. C., Selleslag, D., Bron, D., Amadori, S., Willemze, R., & Muus, P. (2015). Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Annals of hematology, 94(12), 1981-1989. doi:10.1007/s00277-015-2486-9